Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial

Pancreatic Cancer Clinical Trial

— NIRA-PANC  

Official title:

Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03553004
• Other study ID #: IIT-2017-NIRA-PANC
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 22, 2019
• Est. completion date: February 1, 2025

Study information

• Verified date: May 2023
• Source: University of Kansas Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA approved and commercially available for the treatment of ovarian cancer. Its use in this study is investigational.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 18
• Est. completion date: February 1, 2025
• Est. primary completion date: April 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Screening tumor tissue analysis positive with germline or somatic mutation in genes involved in DNA repair.

• Ability of participant or Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent.

• Able to swallow oral study drug

• Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas

• Measurable disease

• Patients with history of other, non-pancreatic cancers with no evidence of active disease are eligible.

• Participants who have had any prior chemotherapy as first line and/or second line therapy for metastatic disease are eligible to seek enrollment. Patients who refuse chemotherapy or do not tolerate chemotherapy are eligible.

• Patients must have adequate organ function

• Women must have a negative serum pregnancy test within 72 hours to taking study treatment.

• Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use approved forms of contraception prior to study entry, for the duration of study participation, and for 180 days following completion of therapy.

Key Exclusion Criteria:

• Patients simultaneously enrolled in any therapeutic clinical trial

• Patients have had investigational therapy administered within the past 4 weeks

• Current or anticipated use of other investigational agents while participating in this study.

• Patient has had prior treatment with a known poly polymerase inhibitor

• Psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant, breast feeding or expecting to conceive children while receiving study treatment and for 180 days after the last dose of study treatment. There is a potential for congenital abnormalities and for this regimen to harm breast feeding infants.

• Patients must not have a known hypersensitivity to the components of niraparib or the excipients

• Patients must not have had major surgery within the last 3 weeks of starting the study and patient must have recovered from any effects of any major surgery

• Patients must not have had radiotherapy encompassing more than 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to Day 1 of protocol therapy

• Patients must not be immuno-compromised. Patients with splenectomy are allowed.

• Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment

• Patients must not have current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the patient's participation for the full duration of the study treatment or that makes it not in the best interest of the patient to participate

• Patients must not have known, symptomatic brain or leptomeningeal metastases

• Patient must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Niraparib Treatment
Niraparib treatment by mouth (oral)

Locations

Country	Name	City	State
United States	University of Kansas Cancer Center - Clinical Research Center	Fairway	Kansas
United States	University of Kansas Cancer Center - North	Kansas City	Missouri
United States	University of Kansas Cancer Center - West	Kansas City	Kansas
United States	University of Kansas Cancer Center - Lee's Summit	Lee's Summit	Missouri
United States	University of Kansas Cancer Center - Overland Park	Overland Park	Kansas
United States	The University of Kansas Cancer Center	Westwood	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
University of Kansas Medical Center	Tesaro, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	Defined as the percentage of participants with overall response to therapy at 8 weeks, defined as Partial Response or Complete Response (PR + CR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)	8 weeks
Secondary	Progression Free Survival (PFS)	Calculated as the percentage of participants with PFS from the time of initial study treatment until the time of progression, defined per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).	Up to 5 years
Secondary	Overall Survival (OS)	Calculated as the average length of time of survival from the time of initial study treatment until the time of death from any cause.	Up to 5 years
Secondary	Disease Control	Calculated as the percentage of participants that achieve any of the following at 8 weeks: complete response, partial response, or stable disease, as defined by RECIST v1.1	8 weeks
Secondary	Duration of Response	Calculated as the average length of time between response to treatment and disease progression, defined per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).	Up to 5 years
Secondary	Proportion of participants with adverse events (AEs)	Defined per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	Up to 5 years